Congress To Forge Ahead With Misconduct Hearings

WASHINGTON—Although many scientists may wish otherwise, the political debate over scientific misconduct is not likely to end anytime soon. Despite the decidedly mixed reviews of last month’s two-day grilling by Rep. John Dingell (D-Mich.) of MIT biologist David Baltimore and others involved in investigating allegations of error stemming from a 1986 Cell paper, Congress seems eager to extend the discussion. Two more congressional panels have scheduled hearings this month on the to

Written byJeffrey Merivs
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

WASHINGTON—Although many scientists may wish otherwise, the political debate over scientific misconduct is not likely to end anytime soon. Despite the decidedly mixed reviews of last month’s two-day grilling by Rep. John Dingell (D-Mich.) of MIT biologist David Baltimore and others involved in investigating allegations of error stemming from a 1986 Cell paper, Congress seems eager to extend the discussion. Two more congressional panels have scheduled hearings this month on the topic, and legislation is being drawn up that would require universities and other institutions to improve their procedures to root out and prevent misconduct.

At the same time, federal regulations are expected to appear shortly on how universities and other institutions must respond to allegations of misconduct. The rules, now being polished in last-minute negotiations between NIH and the Office of Management and Budget, are the final steps in fleshing out legislation passed in 1985.

And scientists have not ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies